Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426034 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL12957767 | 1.00 | ALDH1A1 (0.63) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL12424461 | 0.95 | ALDH1A1 (0.57) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL12683453 | 0.90 | ALDH1A1 (0.49) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL15014631 | 0.90 | ALDH1A1 (0.49) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL30497381 | 0.90 | ALDH1A1 (0.49) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL15014577 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL18525632 | 0.81 | CHRM2 (0.44) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL12424603 | 0.81 | JAK3 (0.46) | ALDH1A1LMNAMEN1KMT2AMAPT | |
| SCHEMBL12957659 | 0.80 | IRAK4 (0.46) | ALDH1A1LMNAMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435428-B2 | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170145044-A1 | Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435428-B2 | Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease | JAK1, JAK2, JAK3 | ALDH1A1 2726/4885LMNA 4486/4885MEN1 3334/4885 |
| US-20170145044-A1 | Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease | JAK1, JAK2, JAK3 | ALDH1A1 2726/4885LMNA 4486/4885MEN1 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.